Estimated Spending on Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa

Beremagene geperpavec (B-VEC) is a topical gene therapy FDA-approved in 2023 for both recessive and dominant dystrophic epidermolysis bullosa (DEB). US spending on B-VEC therapy was estimated to reach $805 million in the first three years post-approval, with a lifetime cost of $15 and $17 million per patient with recessive or dominant DEB, respectively.